AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02185859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The lidocaine group (Group L)- 1% lidocaine 40 mL is prepared in a 50 mL syringe; A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. (Group L subjects are administered lidocaine 2 mg/kg for 15 minutes immediately after the anesthesia induction, and then lidocaine 2 mg/kg/h is continuously injected. The dose of lidocaine and magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.)
Study NCT02185859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: the magnesium group (Group M)- MgSO4 4g 40 mL is prepared in a 50 mL syringe.) A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. The dose of magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.
Study NCT02185859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: the control group (Group C) - 0.9% normal saline 40 mL is prepared in a 50 cc syringe. A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room.Group C subjects are administered the same dose of normal saline.
Study NCT00543959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0533
Description: Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.
Study NCT00543959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
Study NCT00543959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pioglitazone
Description: pioglitazone 45mg. Study period is a total of 24 wks.
Study NCT02905851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feedback group
Description: Monitoring ability to use teledermatology to modify antibiotic burden
Study NCT02905851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non Feedback group
Description: To use as control to see if antibiotic burden has been reduced in the active feedback group
Study NCT01795170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Lysine Restricted Diet
Description: Daily lysine intake will be managed to maintain a plasma lysine level of 50-80 µmol/L (normal range: 52-196 µmol/L). Diet prescriptions will be based on international guidelines for glutaricaciduria type I, another inborn error of lysine catabolism. In order to meet the recommended daily protein intake (DRI) \[23,24\], the diet may include commercially available lysine-free amino acid formulas approved for use in conditions affecting lysine metabolism, as well as commercially available low-protein products based on the participant's taste.
Study NCT01795170 — intervention group
Intervention type: DRUG
Intervention: Pyridoxine
Description: All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
Study NCT02741518 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: This is pre-screened fecal material that has been encapsulated
Study NCT02741518 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: These are capsules that have no fecal material in them.
Study NCT02384798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: noninvasive ventilatory support
Description: noninvasive ventilatory support with 5-minute ramp and positive end expiratory pressure (PEEP) of 5 cm H2O for 30 minutes, then there will be the interval aerobic training on a treadmill added to resistance exercises
Study NCT02384798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interval training
Description: interval training
Study NCT02384798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interval training
Description: interval training
Study NCT04044170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
Study NCT01278472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Port Cholecystectomy
Description: Using transumbilical single port device: SILS Port
Study NCT01411085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone + Desipramine
Study NCT01278472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4 Port Cholecystectomy
Description: using 4 separate skin incisions and 2 5mm and 2 12 mm conventional ports
Study NCT00632788 — intervention group
Intervention type: OTHER
Intervention: acute myocardial infarction checklist
Description: For every patient fulfilling the criteria of enrollment, an acute myocardial infarction checklist was incorporated into the patient's medical records at emergency department immediately after a diagnosis of acute ST-elevation myocardial infarction was made. All the time sequences concerning different managements at different locations were recorded by nurses and/or physicians as instructions on the checklist.
Study NCT01310205 — intervention group
Intervention type: DRUG
Intervention: SCV-07
Description: This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
Study NCT01675544 — intervention group
Intervention type: PROCEDURE
Intervention: Electrocardiogram
Description: EKG voltage changes between admission and discharge
Study NCT01675544 — intervention group
Intervention type: PROCEDURE
Intervention: Six minute walk test
Study NCT02817932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Study NCT02482818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
Study NCT02482818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control-Placebo
Description: A control substance, Lactose is administered in place of Pregabalin.
Study NCT02746224 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initially dissection of inferior mesenteric vein
Description: Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1A the surgical technique initially dissects the inferior mesenteric vein (IMV)
Study NCT02746224 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initially dissection of inferior mesenteric artery
Description: Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1B the surgical technique initially dissects the inferior mesenteric artery.
Study NCT02746224 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Latero-terminal colorectal anastomosis
Description: The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
Study NCT02746224 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Termino-terminal colorectal anastomosis
Description: The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
Study NCT00904033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol tablet taken once per week.
Study NCT00904033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise consisting of progressive walking and resistance band training
Study NCT00904033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Study NCT01088048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally
Study NCT01088048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered intravenously
Study NCT01088048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine administered intravenously
Study NCT01088048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab administered intravenously
Study NCT01088048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine administered orally
Study NCT01088048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus administered orally twice daily until disease progression
Study NCT01088048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib administered as a subcutaneous injection
Study NCT01088048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.
Study NCT01088048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide administered orally
Study NCT03398499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIOFOR (Med & Life)
Description: Device: VIOFOR (Med \& Life) Magnetic-light applicators, generating a slow-changing electromagnetic field and light ener-gy (830 nm and 640 nm), emitted from LEDs during a physiotherapeutic treatment application parameters: frequency of basic field pulses: 180-195 Hz frequency of packet the field pulses: 12.5 Hz-29 Hz magnetic induction: 15 μT wavelength of light: 830 nm and 640 nm Duration: 10 min number of treatments: 10
Study NCT04901780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pragmatic posterior capsular stretch
Description: pragmatic posterior stretch is used to increase the length of the posterior capsule
Study NCT04901780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cross body stretch
Description: crossbody stretch performed by an individual
Study NCT03226197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester drink
Description: Ketone ester drink
Study NCT02834793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo in Randomization phase.
Study NCT02834793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perampanel
Description: Participants will receive perampanel in Randomization phase, open-label Extension A, and open-label Extension B.
Study NCT02834793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Participants will receive perampanel in Randomization phase, open-label Extension A, and open-label Extension B.
Study NCT01320137 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood withdrawal
Description: Blood sampling
Study NCT02089893 — intervention group
Intervention type: DEVICE
Intervention: Fundus photography
Description: Non-mydriatic fundus photographs
Study NCT02049541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor BKM120
Description: Will be supplied to each patient on the first day of each cycle. It will subsequently be self administered by the patient themselves daily on days 1-28 of every 28 day cycle
Study NCT02049541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV (intervenously) on days 2, 8, 15, and 22 of cycle 1, and subsequently on day 1 of cycles 3, 5, 7, 9, and 11.
Study NCT02049541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamics
Description: Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline.
Study NCT02049541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative studies
Description: Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission. In addition, patients with peripheral blood involvement at enrollment will have peripheral blood drawn for all planned research correlates.
Study NCT01874340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at predefined visits over the 6-month treatment phase.
Study NCT01874340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 will be administered at predefined visits over the 6-month treatment phase.
Study NCT02506803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC-GEMABR
Description: NAC-GEMABR regimen includes gemcitabine 1000mg/m2 plus nab-paclitaxel 125mg/m2 3 times weekly 1week rest.
Study NCT00555061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin Ointment, 1%
Description: 1% Ointment
Study NCT01358721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (Anti-PD-1)
Description: Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response
Study NCT01358721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (Anti-PD-1)
Description: Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response
Study NCT01358721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (Anti-PD-1)
Description: Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response
Study NCT06273696 — intervention group
Intervention type: DEVICE
Intervention: ShangRing
Description: The ShangRing is a sterile, single use, disposable male circumcision (MC) device that consists of two concentric plastic rings, the inner of which is lined by a silicone pad, which provides a smooth and non-bio reactive surface against the surgical wound. The outer ring consists of 2 halves which are hinged together at the same end. On each side of the halves there is a locking clasp which allows for locking itself with inner ring. The ShangRing device is removed seven days after placement.
Study NCT02505828 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Articular punction, salivary samples, blood sample
Study NCT02538393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006) Film-coated tablet
Description: Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 \* 200 mg) in fasting state in Treatment A
Study NCT02538393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006) Oral suspension
Description: Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 \* 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.
Study NCT01145677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate 100-300 mg/day orally twice per day
Study NCT04259918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Description: Applying 30 or 60 cmH2O of alveolar recruitment maneuver 5 times every 5 min at the end of bariatric surgery
Study NCT04259918 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitment maneuver
Description: Applying 30 or 60 cmH2O of alveolar recruitment maneuver 5 times every 5 min at the end of bariatric surgery
Study NCT01334619 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: appropriate volume of 0.5% ropivacaine
Description: initial concentration: 30 ml, subsequently varied at a ratio of 1: 1.2 for each consecutive patient according to the response of the previous patient, until 5 up-and-down cycles completed.
Study NCT00970684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg on day 1 of a 21-day cycle
Study NCT00970684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 on day 1
Study NCT00970684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 900 mg/m2 on days 1, and 8,
Study NCT02616588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veteran Patient Navigator and Social Work Intervention
Description: Each study participant will receive a veteran patient navigator intervention which consists of five study visits consisting of advance care planning, pain/symptom management, and education about hospice and palliative care. When clinically indicated, patients will be referred to a social work intervention providing psychosocial care and support.
Study NCT02088138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Functional electrical stimulation twice per week for eight weeks totaling sixteen sessions.
Study NCT02088138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation placebo
Description: Functional electrical stimulation in the sensory threshold level, twice a week for eight weeks, totaling sixteen sessions.
Study NCT05114642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skeletal Class III Malocclusion Treatment with Face Mask Group
Description: Expanding the maxilla, which is narrower than the mandible in the transverse dimension, using a rapid maxillary expansion device and protraction of the maxilla, which is located behind in the sagittal dimension, forward using the face-mask appliance.
Study NCT02056262 — intervention group
Intervention type: OTHER
Intervention: Dental cavity evaluation
Description: The dental cavities present will be evaluated using the ICDAS (International Caries Detection and Assessment System).
Study NCT01770132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: porfimer sodium
Description: Given IV
Study NCT02056262 — intervention group
Intervention type: BIOLOGICAL
Intervention: Saliva sampling
Description: A saliva sample will be harvested.
Study NCT02056262 — intervention group
Intervention type: BIOLOGICAL
Intervention: Plaque sampling
Description: Plaque samples from a healthy tooth and a tooth with a cavity will be harvested.
Study NCT00084136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 400 mg taken orally daily
Study NCT00084136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine (enteric-coated)
Description: 400 mg taken orally daily
Study NCT00084136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600 mg taken orally daily
Study NCT00084136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 200 mg taken orally daily
Study NCT00084136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200 mg/300 mg taken orally once daily
Study NCT00084136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/Zidovudine
Description: 150 mg/300 mg taken orally twice daily
Study NCT03189238 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peri-urethral and clitoral injections
Description: Peri-urethral and clitoral injections
Study NCT03189238 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Peri-urethral and clitoral injections
Description: Peri-urethral and clitoral injections
Study NCT03476590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new model of ambulatory care with use of of non-invasive vital signs assessment and telemedicine
Description: The report of symptoms and physical examination will be obligatory performed by the ACP nurse. Self-condition and quality of life assessment at every visit will be based on EQ-5D questionnaire and VAS 10-points scale Hemodynamic assessment - the ACP nurse will perform impedance cardiography (cardiomonitor) and bioimpedance (scale). The parameters measured by ICG and bioimpedance will be assessed with respect to individually defined target values for: heart rate (HR), systolic and diastolic blood pressure (SBP and DBP), thoracic fluid content (TFC) and its change (delta TFC), change of body mass and total body water (delta TBW).~Supervising physician will confront ICG/bioimpedance results with the patient's clinical data and give final remote recommendations.